Thromboembolic disorders:

Indications for KENGREAL:

As adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.


Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.


Not established.


Significant active bleeding.


Increased risk of bleeding. Discontinue 1hr prior to labor, delivery or neuraxial blockade. Pregnancy. Nursing mothers.

Pharmacologic Class:

P2Y12 platelet inhibitor (ATP analog).


Administer clopidogrel or prasugrel after infusion is discontinued.

Adverse Reactions:

Bleeding, renal impairment, dyspnea, hypersensitivity reactions.

Generic Availability:


How Supplied:

Single-use vial (10mL)—1, 10

Pricing for KENGREAL

50mg vial (Qty: 1)
Appx. price $774